سعر سكايريزي 75 مجم /0.83 مل 2 حقنة معبأة 2025

Skyrizi (risankizumab) 75 mg/0.83 mL solution for subcutaneous injection, pack of 2 prefilled syringes (one 150 mg dose), AbbVie; a humanised IgG1 anti-IL-23 (p19) monoclonal antibody.

• Moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy.Population: Adults and children >=6 yearsDailyMed (U.S. National Library of Medicine)
• Active psoriatic arthritis in adults and pediatric patients 6 years and older.Population: Adults and children >=6 yearsDailyMed (U.S. National Library of Medicine)

• Most common (>=1%) in plaque psoriasis and psoriatic arthritis: upper respiratory infections, headache, fatigue, injection site reactions and tinea infections.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to risankizumab or any excipient.International label, equivalent formulation · European Medicines Agency (EMA) EPAR product information
• Clinically important active infections (e.g. active tuberculosis).International label, equivalent formulation · European Medicines Agency (EMA) EPAR product information
• History of serious hypersensitivity reaction to risankizumab-rzaa or any excipient.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Serious hypersensitivity reactions including anaphylaxis have been reported; discontinue and treat if they occur.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• May increase risk of infections; do not start during a clinically important active infection until resolved or adequately treated.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Evaluate for tuberculosis before starting treatment.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Live vaccinesAvoid use of live vaccines during treatment.DailyMed (U.S. National Library of Medicine)

• Limited data (<300 pregnancy outcomes); animal studies do not indicate harmful reproductive effects; as a precaution, preferably avoid use during pregnancy. Women of childbearing potential should use effective contraception during treatment and for at least 21 weeks after.International label, equivalent formulation · European Medicines Agency (EMA) EPAR product information
• Available pharmacovigilance and clinical trial data are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse outcomes.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Unknown whether excreted in human milk; a risk to the breast-fed infant cannot be excluded in the first days after birth; decide whether to discontinue breast-feeding or therapy.International label, equivalent formulation · European Medicines Agency (EMA) EPAR product information

• Risankizumab: Selectively binds the p19 subunit of human IL-23 and inhibits its interaction with the IL-23 receptor, reducing release of pro-inflammatory cytokines and chemokines.